GlaxoSmithKline

NYSE: GSK
$29.43
+$0.07 (+0.2%)
Closing price September 30, 2022
Friday's top analyst upgrades and downgrades included Chipotle Mexican Grill, CrowdStrike, First Solar, Fortinet, Franklin Resources, GSK, Intel, Nvidia, Shoals Technologies, Spirit AeroSystems,...
Friday's top analyst upgrades and downgrades included Alcoa, Blue Apron, Brixmor Property, Enterprise Products Partners, FIGS, GSK, Healthcare Realty Trust, Nordstrom, Range Resources, Southwestern...
Monday's top analyst upgrades and downgrades included Chewy, Cloudflare, Coca-Cola, Doximity, Ideanomics, GlaxoSmithKline, Micron Technology, SoFi Technologies, Teladoc Health, Twitter and Walmart.
Friday afternoon's analyst upgrades and downgrades included BigCommerce, Citrix, GlaxoSmithKline, Nikola, Regeneron, Shake Shack and more.
Thursday’s top analyst upgrades and downgrades included Analog Devices, Activision Blizzard, BP, Clorox, EA, MGM PayPal, Square and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Alexion, DraftKings, Inovio, Netflix, Snowflake and more.
Thursday's top analyst upgrades and downgrades included Apple, Best Buy, Electronic Arts, FireEye, Match, PayPal, Qualcomm and ViacomCBS.
Wednesday's top analyst upgrades and downgrades included Altria, Boeing, Coca-Cola, GlaxoSmithKline, Halliburton, Kroger, Netflix and Pioneer Natural Resources.
Vir Biotechnology shares jumped on Tuesday after the firm announced that it would be expanding its late-stage COVID-19 study in conjunction with GlaxoSmithKline.
Many health care products become much more popular because of endorsements and advertising efforts. It is a longstanding practice that has come under fire by both political parties in the United...
Nvidia has announced it will partner with GlaxoSmithKline to apply its artificial intelligence and supercomputers for the drug and vaccine discovery process.
GlaxoSmithKline has announced that it is acquiring a 10% stake in the German biopharma firm CureVac.
There are still a lot of questions for Amarin must figure out before it gets back on track. For investors, the question is whether it is the market recovery that is lifting the stock instead of the...
Amarin stock was absolutely crushed at the tail end of March, and now the company is dealing with the fallout. Investors will be asking a lot of tough questions. Namely, is Amarin viable going...
Co-Diagnostics is on many shortlists of companies with partial medical solutions to slow the coronavirus outbreak. Investors have been on a roller-coaster ride. Is the stock ready to run?